Candel Therapeutics, Inc. (CADL) Stock Overview
Explore Candel Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Candel Therapeutics, Inc. (CADL)
Key Financials
Key Financials
Market Cap
524.9M
P/E Ratio
-9.66
EPS (TTM)
$-0.98
ROE
-0.60%
CADL Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Candel Therapeutics, Inc. (NASDAQ: CADL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Candel Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CADL on the NASDAQ shows an RSI of 49.57, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $8.73 for the NASDAQ listing.
Key metrics behind Candel Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -9.66 and a market capitalization of 524.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CADL on the NASDAQ.